MapLight News

MapLight Therapeutics Appoints Maria Walker to Board of Directors Walker brings 30+ years of investment, operational, and advisory experience SAN FRANCISCO AND BOSTON, APRIL 3,

MapLight Therapeutics Announces Completion of Phase 1 Clinical Trial for Novel M1/M4 Muscarinic Agonist in Development for Schizophrenia and Alzheimer’s Disease Psychosis Extended-release ML-007 was

MapLight Drug Discovery Technology Recognized as a Leading Artificial Intelligence Platform MapLight’s drug discovery algorithm has been recognized with first-place rankings by Therapeutics Data Commons

MapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of Central Nervous System Therapeutics Funding will support development of multiple clinical candidates

MapLight Therapeutics Announces Successful Completion of Second Phase 1 Clinical Trial of the Novel Muscarinic Receptor Agonist ML-007 Study assessed safety, tolerability, and pharmacokinetics (PK)

MapLight Therapeutics Appoints Tim Garnett, M.D. to Board of Directors Industry Leader Appointed to MapLight’s Board of Directors    SAN FRANCISCO, July 24, 2023 –

MapLight Therapeutics Appoints Kris Hanson as General Counsel Hanson Brings 25 Years of Experience Advising Public and Private Companies to MapLight as the New Legal

MapLight Therapeutics Appoints Dr. Matthew State and Dr. Ivan Soltesz to Scientific Advisory Board MapLight’s drug discovery expertise is further strengthened by the addition of

Dr. Zeng Brings Deep Expertise in Single-Cell Transcriptomics and Brian Circuit Connectivity to MapLight’s Scientific Advisory Board

Ms. Lykins brings more than 25 years of neuroscience-focused pharmaceutical commercial experience across multiple organizations recognized as leaders in developing and commercializing medicines for central nervous system disorders, including Eli Lilly, Lundbeck, Sunovion and ACADIA Pharmaceuticals.

18.08.2022 MapLight Therapeutics Announces Completion Of Phase 1 Clinical Trial For ML-007, A Novel Therapy For The Treatment Of Schizophrenia And Dyskinesias First in human

Initial study is enrolling healthy patients across seven cohorts to assess safety, tolerability, and pharmacokinetic profile related to ML-007 therapy.

The $1.75M award builds on a $5.5M grant from MJFF announced earlier this month. MapLight also received an $8.1M award from MJFF in 2020.

MapLight’s promising platform continues to garner support from leading Parkinson’s research foundation.

Dr. Foff Joins MapLight to Help Further Advance the Company’s Portfolio of Novel Therapeutics for Patients with Disorders of the Central Nervous System (CNS).

Results will inform identification of novel drug targets and therapeutic strategies to address anxiety and depression related to Parkinson’s disease neurodegeneration.

Interim data from Phase 1 clinical trial with repeated dosing in healthy volunteers demonstrates positive safety and tolerability profile for ML-004.

This new grant totaling more than $16.5 million will serve our mission to find a cure for Parkinson’s and improved treatments for those living with the disease today.